Indeed, PRL is expressed in more than half of prostate tumors (including local, locally advanced, and hormone refractory) and over 60% metastases [2,3], and its level of expression in primary tumors is positively associated with high Gleason score (i.e., high disease severity) [2]. Here, PRL is linked to prostate neoplasm.